| abstract |
The present invention relates to a process for preparing a polypeptide with anti-Ig antibody activity, which has no deactivation activity by isomerization of aspartyl residues and having affinity for a target molecule, represented by IgE, equal to or greater than the polypeptide. modified, to the antibody molecule obtained by the process, to the nucleic acid molecule encoding the antibody, to a pharmaceutical composition administered in the treatment of an IgE-mediated disorder, to a mammal, and to the use of a dean antibody molecule for the manufacture of a drug for reducing or preventing production. of IgE-mediated histamine in a mammal. |